Tvardi Therapeutics, Inc. (TVRD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q1 '14: 12.1M Q2 '14: 3.1M Q3 '14: 3.2M Q4 '14: 3.2M Q1 '15: 3.5M Q2 '15: 3.4M Q3 '15: 4.7M Q4 '15: 3.8M Q1 '16: 3.3M Q2 '16: 2.5M Q3 '16: 86K Q4 '16: 86K Q1 '17: 990K Q2 '17: 911K Q3 '17: 911K Q4 '17: 911K Q1 '19: 17.9M Q2 '19: 20.2M Q3 '19: 20.9M Q4 '19: 19.9M Q1 '20: 23.6M Q2 '20: 24M Q3 '20: 27.5M Q4 '20: 135.1M Q1 '21: 128.9M Q2 '21: 123.3M Q3 '21: 134.3M Q4 '21: 23M Q1 '22: 25.9M Q2 '22: 48.9M Q3 '22: 39.4M Q4 '22: 41.9M Q1 '23: 43.2M Q2 '23: 27.2M Q3 '23: 21.2M Q4 '23: 21M Q1 '24: 16.9M Q2 '24: 11M Q3 '24: 8.7M Q4 '24: 7.1M Q1 '25: 7.6M Q1 '15 Q3 '16 Q1 '19 Q3 '20 Q1 '22 Q3 '23 Q1 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '13: -237K Q1 '14: -2.1M Q2 '14: -12.8M Q3 '14: -15.8M Q4 '14: -18.1M Q1 '15: -19.4M Q2 '15: -21.4M Q3 '15: -19.8M Q4 '15: -25.2M Q1 '16: -31.5M Q2 '16: -39M Q3 '16: -45.8M Q4 '16: -58.4M Q1 '17: -69.7M Q2 '17: -66M Q3 '17: -67.2M Q4 '17: -59.5M Q1 '18: -54.3M Q2 '18: -62.5M Q3 '18: -70M Q4 '18: -77.4M Q1 '19: -83.4M Q2 '19: -89.7M Q3 '19: -103.7M Q4 '19: -111.7M Q1 '20: -118.5M Q2 '20: -120.3M Q3 '20: -102.9M Q4 '20: 5.4M Q1 '21: 11.8M Q2 '21: 6.8M Q3 '21: 22.7M Q4 '21: -89.1M Q1 '22: -93.4M Q2 '22: -67M Q3 '22: -89.8M Q4 '22: -87.5M Q1 '23: -87.3M Q2 '23: -115.1M Q3 '23: -120.2M Q4 '23: -121.5M Q1 '24: -123.5M Q2 '24: -98.4M Q3 '24: -75.1M Q4 '24: -28.1M Q1 '25: -2.8M Q2 '25: -4.5M Q3 '25: -4.7M Q4 '25: -26.7M Q1 '26: -29.4M Q2 '26: -27.2M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '13: -4M Q1 '14: -4.7M Q2 '14: -13.7M Q3 '14: -15.7M Q4 '14: -17.7M Q1 '15: -19.1M Q2 '15: -21.1M Q3 '15: -19.3M Q4 '15: -24.7M Q1 '16: -30.7M Q2 '16: -38.1M Q3 '16: -44.8M Q4 '16: -57.3M Q1 '17: -68.8M Q2 '17: -65M Q3 '17: -65.9M Q4 '17: -58.1M Q1 '18: -52.7M Q2 '18: -60.6M Q3 '18: -67.5M Q4 '18: -74M Q1 '19: -79.2M Q2 '19: -85M Q3 '19: -98.4M Q4 '19: -106.4M Q1 '20: -113.3M Q2 '20: -115.4M Q3 '20: -99.1M Q4 '20: 8.4M Q1 '21: 14M Q2 '21: 8.4M Q3 '21: 23.9M Q4 '21: -88.4M Q1 '22: -92.9M Q2 '22: -66.3M Q3 '22: -88.5M Q4 '22: -85.5M Q1 '23: -84.4M Q2 '23: -111.7M Q3 '23: -116.5M Q4 '23: -118.5M Q1 '24: -96M Q2 '24: -71.5M Q3 '24: -49M Q4 '24: -29.4M Q1 '25: -34.8M Q2 '25: -23.6M Q3 '25: -23.6M Q4 '25: -18.2M Q1 '26: -15.4M Q2 '26: -26.1M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q4 '13: 2.8M Q1 '14: 1.6M Q2 '14: -15.8M Q3 '14: -16.9M Q4 '14: -17.6M Q1 '15: -19.8M Q2 '15: -19.8M Q3 '15: -23.1M Q4 '15: -21.5M Q1 '16: -26.1M Q2 '16: -33.3M Q3 '16: -38.4M Q4 '16: -47.4M Q1 '17: -59.2M Q2 '17: -59.7M Q3 '17: -56.6M Q4 '17: -54.8M Q1 '18: -51.7M Q2 '18: 1.3M Q3 '18: -9.4M Q4 '18: -22.3M Q1 '19: -31.4M Q2 '19: -97.3M Q3 '19: -102.4M Q4 '19: -109.2M Q1 '20: -120M Q2 '20: -122.8M Q3 '20: -118.7M Q4 '20: -5.5M Q1 '21: 9.1M Q2 '21: 15.7M Q3 '21: 23.2M Q4 '21: -60.1M Q1 '22: -61.9M Q2 '22: -45.4M Q3 '22: -56.5M Q4 '22: -78.7M Q1 '23: -87.8M Q2 '23: -103.8M Q3 '23: -98.2M Q4 '23: -92.1M Q1 '24: -87.9M Q2 '24: -43.8M Q3 '24: -30.8M Q4 '24: -18.3M Q1 '25: 4.5M Q2 '25: -25M Q3 '25: -22.6M Q4 '25: -23.5M Q1 '26: -21.7M Q2 '26: -25M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q2 '15: -19.9M Q3 '15: -23.2M Q4 '15: -21.5M Q1 '16: -26.1M Q2 '16: -33.4M Q3 '16: -39M Q4 '16: -48.1M Q1 '17: -59.9M Q2 '17: -60.2M Q3 '17: -56.7M Q4 '17: -54.9M Q1 '18: -51.7M Q2 '18: 1.2M Q3 '18: -9.4M Q4 '18: -22.4M Q1 '19: -31.4M Q2 '19: -97.3M Q3 '19: -102.5M Q4 '19: -109.2M Q4 '22: -78.8M Q3 '24: -33.9M Q4 '24: -19.4M Q2 '15 Q1 '16 Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q4 '19 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '13: 3.7M Q2 '13: 16M Q3 '13: 4.3M Q1 '14: 15.7M Q2 '14: 22.6M Q3 '14: 22.7M Q1 '15: 22.8M Q2 '15: 22.8M Q3 '15: 25.5M Q1 '16: 27.3M Q2 '16: 27.3M Q3 '16: 27.3M Q1 '17: 27.3M Q2 '17: 32.2M Q3 '17: 32.6M Q1 '18: 32.7M Q2 '18: 33.3M Q3 '18: 38M Q1 '19: 39.6M Q2 '19: 39.8M Q3 '19: 44.5M Q1 '20: 46.7M Q2 '20: 46.8M Q3 '20: 46.9M Q1 '21: 49.9M Q2 '21: 50.1M Q3 '21: 50.1M Q1 '22: 53.5M Q2 '22: 53.6M Q3 '22: 53.7M Q1 '23: 53.9M Q2 '23: 54M Q3 '23: 54.2M Q1 '24: 1.5M Q2 '24: 2.6M Q3 '24: 2.6M Q1 '25: 2.6M Q2 '25: 8.5M Q3 '25: 9.4M Q1 '26: 9.4M Q2 '26: 9.4M Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-27.00 -18.00 -9.00 0.00 9.00 18.00 27.00 Q4 '13: -1.71 Q1 '14: -1.45 Q2 '14: -1.94 Q3 '14: -1.16 Q4 '14: -0.85 Q1 '15: -0.84 Q2 '15: -0.93 Q3 '15: -0.83 Q4 '15: -1.00 Q1 '16: -1.18 Q2 '16: -1.41 Q3 '16: -1.64 Q4 '16: -2.10 Q1 '17: -2.52 Q2 '17: -2.33 Q3 '17: -2.29 Q4 '17: -1.91 Q1 '18: -1.61 Q2 '18: -1.84 Q3 '18: -1.97 Q4 '18: -2.06 Q1 '19: -2.11 Q2 '19: -2.17 Q3 '19: -2.40 Q4 '19: -2.49 Q1 '20: -2.55 Q2 '20: -2.51 Q3 '20: -2.12 Q4 '20: 0.08 Q1 '21: 0.23 Q2 '21: 0.16 Q3 '21: 0.49 Q4 '21: -1.74 Q1 '22: -1.79 Q2 '22: -1.26 Q3 '22: -1.67 Q4 '22: -19.12 Q1 '23: -19.09 Q2 '23: -19.59 Q3 '23: -19.68 Q4 '23: -26.26 Q4 '25: -3.26 Q1 '26: -0.27 Q2 '26: 0.04 Q1 '14 Q3 '15 Q1 '17 Q3 '18 Q1 '20 Q3 '21 Q1 '23 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.